Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the Prospectus with details from their quarterly report filed on the same date. The supplement relates to the issuance of up to 2,433,789 shares of common stock underlying previously issued warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with a last reported sales price of $0.35 per share as of August 12, 2024. The Quarterly Report attached to the prospectus supplement includes financial statements indicating a net loss of $14.3 million for the six months ended June 30, 2024, and a decrease in cash and cash equivalents from $2.578 million to $59,000. The company has incurred a total deficit of $139.8 million since inception and acknowledges a high...Show More

Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the Prospectus with details from their quarterly report filed on the same date. The supplement relates to the issuance of up to 2,433,789 shares of common stock underlying previously issued warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with a last reported sales price of $0.35 per share as of August 12, 2024. The Quarterly Report attached to the prospectus supplement includes financial statements indicating a net loss of $14.3 million for the six months ended June 30, 2024, and a decrease in cash and cash equivalents from $2.578 million to $59,000. The company has incurred a total deficit of $139.8 million since inception and acknowledges a high degree of risk in investing in their securities. The report also details the company's reliance on third-party CROs for clinical trials, which poses risks to the timing and quality of their trials. Panbela Therapeutics has faced challenges with maintaining payments to their CRO for the ASPIRE trial, which could lead to delays if unresolved. The company's ability to continue as a going concern is dependent on obtaining additional financing and successful development and commercialization of their product candidates.